P1.01-70 Efficacy and Safety of Second- Or Third-Line Nab-Paclitaxel + Durvalumab in Patients With Advanced NSCLC (ABOUND.2L+)
Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.626
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2018
Authors
Publisher
Elsevier BV